Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06092944
Other study ID # RISS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date December 30, 2024

Study information

Verified date October 2023
Source Fuling Central Hospital of Chongqing City
Contact Luo fuchao, MD
Phone +8613896658090
Email luokyyx@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective is to investigate the safety and effectiveness of rhomboid intercostal and subserratum plane (RISS) block for postoperative analgesia after minimally invasive McKeown esophagectomy (MIE-McKeown).


Description:

Rhomboid intercostal and subserratum plane block (RISS) is a nerve block technique in which local anesthetics are injected into the rhomboid-intercostal muscle planes and the serratus anterius-intercostal muscle planes, and the intercostal nerve is blocked by diffusion of local anesthetics. It is confirmed that RISS can provide analgesia not only in the front half of the chest, but also in the upper abdomen. However, the efficacy of RISS in minimally invasive surgery for esophageal cancer has not been proven. The investigators placed catheters on the RISS plane and continuously injected local anesthetics to investigate whether RISS is effective and safe in minimally invasive esophageal cancer surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 96
Est. completion date December 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients received MIE-McKeown surgery and were confirmed by postoperative pathology; Age 18-75 years old - body mass index (BMI) : 18.5~23.9kg/m2; - American Society of Anesthesiologists (ASA) grade: ?~?; - Clear consciousness, no cognitive impairment; - Patients informed to participate in the study and signed informed consent. Exclusion Criteria: - Infection of the puncture site, abnormal platelet or coagulation function; - Patients with drug allergy involved in this study; - Long-term use of analgesic, sedative drugs or a history of heavy drinking; - Patients with chronic painful diseases; - With severe heart, liver, kidney and lung dysfunction; - Infectious diseases, blood, immune, circulatory system diseases; -Communication barriers, can not cooperate with the scale assessment; - - Other situations not suitable for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Catheterization
Before the operation,the patient was placed in the left lateral position.The catheter(soft tip epidural catheter 20-gauge-100 cm) was placed at the rhomboid-intercostal plane under ultrasound guidance at the T5-T6 level, followed by ultrasound-guided catheter placed in the anterior serrated muscle plane at the T7-9 level?
Single nerve block
Before the operation,40milliliters of 0.3% ropivacaine was injected into the rhomboid-intercostal fascia plane and anterior serrated muscle plane respectively under the guidance of ultrasound.
Continuous nerve block
After surgery,local anesthetics were injected continuously through catheters.Local anesthetic formula:Ropivacaine 300mg + normal saline, prepared into 150milliliters liquid, background dose 2milliliters/h.
PCIA
After surgery, the patient was given controlled intravenous analgesia. Analgesic pump drug formula:Sufentanil 50ug+ Dezocine 20mg+ Granisetron 10mg+150milliliters saline, continuous dose of 2milliliters/h intravenous pump, single injection dose of 2milliliters, locking time of 20 min

Locations

Country Name City State
China FulingCH Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Luo Fuchao

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analgesic effect patient will be asked to rate their pain level at rest and cough respectively using visual analogue scale(VAS).(0 being no pain, 10 being worst pain imaginable) 2, 6, 12, 24, and 48 hours after surgery
Primary mean arterial pressure (MAP) The mean arterial pressure (MAP)on the monitor at different times was recorded. before anesthesia induction (T0), before skin incision(T1), 5 minutes after skin incision
Primary Heart rate (HR) The Heart rate (HR)on the monitor at different times was recorded. before anesthesia induction (T0), before skin incision(T1), 5 minutes after skin incision
Secondary dizziness The occurrence of dizziness was recorded 24hours after surgery
Secondary lethargy The occurrence of lethargy was recorded 24hours after surgery
Secondary nausea or vomiting The occurrence of nausea /vomiting was recorded 24hours after surgery
Secondary hypotension The occurrence of hypotension was recorded 24hours after surgery
Secondary respiratory depression The occurrence of respiratory depression was recorded 24hours after surgery
Secondary urinary retention The occurrence of urinary retention was recorded 24hours after surgery
Secondary Analgesia satisfaction patient will be asked to rate their Satisfaction with analgesia using verbal rating scales (VRS) .Scores from 1 to 5 represent very dissatisfied, not satisfied, basically satisfied, relatively satisfied, and very satisfied with the analgesic effect, respectively. 24hours after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Completed NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Phase 2
Recruiting NCT06036563 - Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Not yet recruiting NCT05023928 - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer Phase 1
Recruiting NCT03941626 - Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies Phase 1/Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT02988921 - MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy N/A
Completed NCT02979691 - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 Phase 2/Phase 3
Terminated NCT02797405 - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay N/A
Recruiting NCT03347630 - Pre-operative MRI of Esophagus Cancer N/A
Completed NCT00193141 - Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer Phase 2
Recruiting NCT05626309 - Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer N/A
Completed NCT05615129 - Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT04046575 - Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Phase 1
Recruiting NCT06126406 - Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03467529 - Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2